Best Grants for Preschools in Northern Mariana Islands

The NCCIH Multi-Site Feasibility Clinical Trials of Mind and Body Interventions (R01) invites applications for clinical trials focusing on complementary and integrative health approaches. This funding opportunity emphasizes the importance of multisite feasibility trials to gather essential data for planning future efficacy studies. Deadlines for standard and AIDS-related applications range from February 2024 to November 2026, underscoring the urgency for innovative research in high-priority areas.

The BRAIN Initiative seeks to develop innovative tools and approaches for neuroscience research, focusing on cell-specific and circuit-specific processes within the central nervous system. This initiative encourages projects that enhance our understanding of brain architecture and function through novel technologies for characterizing neural components and advancing methods for recording and modulating neural activity. Applications are invited to address significant challenges and promote transformative breakthroughs in neuroscience.

The Childhood Asthma in Urban Settings Clinical Research Network (CAUSE) aims to enhance asthma prevention and treatment in economically disadvantaged pediatric populations. Funded by the NIH, CAUSE supports multi-site clinical studies to identify innovative strategies and treatment targets for asthma. Utilizing systems biology, the network seeks to discover specific disease endotypes suitable for new therapeutic approaches, addressing the high burden of asthma in urban settings.

The National Institute of Allergy and Infectious Diseases (NIAID) is funding research to enhance drug susceptibility testing (DST) for mycobacteria. This initiative aims to improve testing for tuberculosis (TB) and non-tuberculous mycobacterial (NTM) infections, which are on the rise. Current methods are slow and ineffective against drug-resistant strains, making rapid DSTs essential for effective treatment and reducing transmission rates. Innovative approaches, including rapid genotypic and phenotypic methods, will be supported to address these challenges.

The Creative West Artist Fund supports artists and cultural practitioners across 16 states, providing essential funding and resources to enhance their emotional and financial well-being. Rooted in values of Democracy, Wellness, and Belonging, this initiative offers no-strings-attached funding alongside coaching and community care. It aims to empower artists as vital contributors to the creative economy, while promoting equitable and trust-based grantmaking practices. The fund serves to foster a rich creative community through collaboration and support.

The upcoming National Institute of Mental Health (NIMH) funding opportunity aims to explore the effects of HIV immunotherapies on central nervous system (CNS) outcomes. It seeks to identify mechanisms, benefits, and risks associated with these therapies, focusing on overcoming CNS-specific barriers. The initiative encourages collaborations to develop strategies for achieving sustained virologic remission and improving neurological outcomes for individuals with HIV, particularly targeting neurotoxicity and neuroinflammation.

The ALACRITY Research Centers, funded by the National Institute of Mental Health, aim to enhance the effectiveness of mental health interventions for youth and adults. This initiative supports interdisciplinary research to develop innovative approaches for optimizing mental health care access and quality. By fostering collaborations across various fields such as behavioral science and health systems engineering, the program seeks to transform clinical practices and improve outcomes for individuals facing mental health challenges.

The HEAL Initiative aims to enhance therapeutic medical devices through team science research, focusing on the mechanisms that drive their effectiveness. The National Institute of Neurological Disorders and Stroke (NINDS) seeks to improve clinical outcomes by fostering interdisciplinary collaborations. This initiative invites teams with expertise in engineering, biology, and clinical care to explore innovative device-based therapies. By understanding how these devices work, the program hopes to optimize existing technologies and inspire new designs, ultimately improving patient care.

The Rooted Pathways Program, initiated by First Peoples Fund, offers essential support to Native-led arts organizations, fostering their growth and stability. This funding empowers these organizations to thrive in their missions, providing unrestricted operating support and participation in a Learning Cohort. Eligible applicants include Native nonprofits and collectives with budgets under $500,000, and the program aims to uplift artists from U.S. federally recognized tribes. This initiative is part of the Wallace Foundation's broader commitment to enhancing well-being in the arts.

The National Institutes of Health (NIH) invites applications for clinical trials and ancillary studies within its funded research networks. This program supports multi-center trials, emphasizing collaborations and responsive projects. The UG3/UH3 cooperative agreement will fund an initial 2-year planning phase, with a potential 5-year implementation phase. This notice is to prepare applicants for future submissions, as applications are currently not being solicited. Prioritization will be given to studies aligned with network capabilities.

The RFA-FD-23-001 funding opportunity aims to support clinical trials for orphan products targeting rare diseases. It focuses on evaluating the efficacy and safety of treatments to address unmet medical needs. By promoting innovative and collaborative trial designs, the FDA seeks to enhance the approval rates of effective therapies for rare conditions, ultimately benefiting patients and advancing drug development in this critical area.

The NARMS Cooperative Agreement Program aims to enhance antibiotic resistance surveillance in retail food specimens. Funded by the FDA, this initiative strengthens the National Antimicrobial Resistance Monitoring System established in 1996. By improving detection methods and expanding sampling sites, the program seeks to protect public health and align with NARMS objectives, ultimately combating the growing threat of antibiotic resistance in food commodities.

This funding opportunity aims to enhance the development of medical products in rare diseases through innovative natural history studies. By generating high-quality data, the FDA seeks to bridge critical knowledge gaps and eliminate barriers in rare disease research. The initiative focuses on diseases with unmet needs, fostering significant impacts for those affected and facilitating the development of effective therapeutic solutions.

The DOW Combat Readiness – Medical Research Program's FY26 Translational Research Award supports innovative research aimed at improving trauma care outcomes. This program emphasizes hypothesis-driven studies that can transition promising technologies into practical solutions for enhancing casualty survivability. Applicants must provide preliminary data and utilize validated animal models, with a focus on projects that meet a minimum technology readiness level of 4, ensuring a mature translational research effort.

The NIDCD invites R01 grant applications aimed at independent research projects related to the mission of the National Institute on Deafness and Other Communication Disorders. This opportunity promotes workforce development by supporting Early Stage and New Investigators, especially those from underrepresented backgrounds in health sciences. Letters of Intent are encouraged 30 days before the proposal deadline, allowing diverse researchers to collaborate and contribute to vital health-related studies.

The Ultra-Rare Gene-based Therapy (URGenT) Network Resource Access program provides critical support to researchers by offering access to contract research organizations and subject matter experts. This funding opportunity aims to facilitate nonclinical therapeutic development efforts, helping investigators navigate the complexities of manufacturing and planning. Applications are due by 5:00 PM local time, with optional Letters of Intent recommended 30 days prior to the proposal deadline.

The National Institute on Aging (NIA) is set to issue a Notice of Funding Opportunity (NOFO) for randomized controlled trials examining the long-term effects of nutritional interventions on risk factors for age-related chronic conditions. This initiative seeks to enhance understanding of how various dietary practices can influence health throughout the life span, emphasizing the need for studies with at least five years of follow-up. Researchers are encouraged to prepare collaborative proposals in response to this upcoming funding opportunity.

The NIAID aims to enhance our understanding of the interplay between chronic and infectious diseases through innovative precision systems biology research. By utilizing advanced technologies such as multi-omics and artificial intelligence, the initiative focuses on uncovering critical pathways that connect infections to chronic health issues. This multidisciplinary approach leverages longitudinal patient data to inform and improve prevention and treatment strategies, ultimately seeking to provide insights into disease progression and host-pathogen interactions.

The Translational Transplantation Tolerance Cooperative Study Group, supported by the National Institute of Allergy and Infectious Diseases, aims to advance transplant tolerance strategies that promote long-term graft survival without lifelong immunosuppression. This initiative focuses on developing, optimizing, and evaluating methods to induce immune tolerance in allogeneic transplants through collaborative efforts across multiple centers, utilizing translationally relevant models to ensure effective outcomes.

The AHRQ Small Research Projects (R03) program supports short-term research endeavors in primary care, enabling innovative pilot studies, secondary data analysis, and the development of research methodologies. This initiative encourages researchers to explore new technologies and approaches within limited resource frameworks, fostering advancements in healthcare quality and efficiency. Applications are due by 5:00 PM local time of the applicant organization, emphasizing the importance of timely submission.

The HEAL Initiative aims to identify new druggable targets for pain within the understudied proteome. This funding opportunity invites applications for pilot projects that generate preliminary data and tools for exploring these targets. The initiative seeks to enhance research on understudied proteins related to pain management, providing essential funding for biochemical and biological work. This NOFO is part of the NIH's broader effort to develop novel medications that address various aspects of opioid addiction and its consequences.

The Limited Competition Small Grant Program under the NCATS CTSA aims to enhance the research capabilities of scholars transitioning to independent academic translational scientists. This program supports diverse clinical and translational science projects, including pilot studies and methodology development. The R03 grants are designed for short-term projects with limited resources that generate preliminary data for future R01 applications, thereby fostering innovation and advancing health research.

The Limited Competition: Clinical and Translational Science Award (CTSA) Program's Collaborative and Innovative Acceleration Award aims to enhance translational research by fostering collaboration in developing and implementing innovative solutions. This funding opportunity invites applications focused on new approaches and technologies that will improve research impact across various diseases and expedite treatment availability. Eligible applicants include organizations with active CTSA hub prime or partnering awards.

The Outdoor Recreation Legacy Partnership Program (ORLP) is a competitive grant initiative by the National Park Service, aimed at enhancing parks and recreational opportunities in urban, underserved communities. This program supports the acquisition, development, and renovation of outdoor recreation areas through federal funding, addressing the needs of community organizations, local governments, and recognized tribes. Applications are accepted twice a year, before June 1 and November 1.

The Clinical Data, Safety and Statistical Centers (CDSSC) program, supported by the National Institute of Allergy and Infectious Diseases (NIAID), aims to enhance clinical research through comprehensive support. This includes statistical analysis, protocol development, and oversight of safety monitoring in studies related to asthma, autoimmune diseases, and transplantation. By coordinating these efforts, the program seeks to facilitate impactful research outcomes and improve public health outcomes through informed data-driven decisions.

The NIDDK High Risk Multi-Center Clinical Study Implementation Planning Cooperative Agreements (U34) aims to support high-risk, multi-center clinical studies by facilitating early peer review and assessment of study designs. This program helps in the development of necessary operational documents and essential elements for conducting hypothesis-driven studies focused on diseases relevant to NIDDK. Applications are due by 5:00 PM local time, and consulting with NIDDK staff is strongly encouraged.

The National Institute of Allergy and Infectious Diseases (NIAID) is advancing research on immune tolerance through its Collaborative Network. This program aims to clarify the mechanisms of immune tolerance and develop interventions for related diseases, including transplant rejection and autoimmune disorders. Key objectives include conducting clinical trials on tolerogenic strategies and refining immune assays. This initiative is supported by regulations under the Public Health Service Act, ensuring a structured approach to improving patient outcomes.